CVRx (CVRX) Projected to Post Quarterly Earnings on Thursday

CVRx (NASDAQ:CVRX) will likely be releasing its quarterly earnings results before the market opens on Thursday, January 23rd. Analysts expect CVRx to post earnings of ($0.39) per share and revenue of $14,850.00 billion for the quarter. CVRx has set its Q4 2024 guidance at EPS and its FY 2024 guidance at EPS.Investors that are interested in registering for the company’s conference call can do so using this link.

CVRx (NASDAQ:CVRX) last posted its quarterly earnings data on Tuesday, October 29th. The company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.12). CVRx had a negative return on equity of 89.06% and a negative net margin of 123.75%. The firm had revenue of $13.37 million during the quarter, compared to analyst estimates of $13.28 million. During the same period in the prior year, the business posted ($0.43) EPS. On average, analysts expect CVRx to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

CVRx Price Performance

Shares of NASDAQ:CVRX opened at $18.40 on Wednesday. The company’s fifty day moving average is $14.21 and its two-hundred day moving average is $11.20. The company has a market cap of $446.38 million, a P/E ratio of -6.81 and a beta of 1.26. CVRx has a 12-month low of $6.40 and a 12-month high of $29.23. The company has a quick ratio of 10.23, a current ratio of 11.32 and a debt-to-equity ratio of 0.76.

Analyst Ratings Changes

Several equities research analysts recently issued reports on CVRX shares. Canaccord Genuity Group increased their price objective on CVRx from $17.00 to $22.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. Piper Sandler reissued an “overweight” rating and issued a $16.00 price target (up from $13.00) on shares of CVRx in a research report on Wednesday, October 30th. Cantor Fitzgerald restated an “overweight” rating and set a $14.00 price target on shares of CVRx in a report on Wednesday, October 23rd. Craig Hallum upped their price objective on shares of CVRx from $20.00 to $22.00 and gave the company a “buy” rating in a research note on Friday, January 17th. Finally, Lake Street Capital lifted their target price on shares of CVRx from $12.00 to $15.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $17.00.

CVRx Company Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.